» Articles » PMID: 36319704

Therapeutic Plasma Exchange in Multiple Sclerosis Patients with an Aggressive Relapse: an Observational Analysis in a High-volume Center

Overview
Journal Sci Rep
Specialty Science
Date 2022 Nov 2
PMID 36319704
Authors
Affiliations
Soon will be listed here.
Abstract

An evidence-based treatment for a Multiple Sclerosis (MS) relapse is an intravenous administration of 3-5 g of Methylprednisolone. In case of insufficient effect or corticosteroids intolerance, the therapeutic plasma exchange (TPE) is indicated. To assess the clinical effect of TPE in treatment of relapse in patients with relapsing-remitting MS (RRMS), we enrolled 155 patients meeting the following criteria (study period: January 2011 to February 2021): (1) age > 18, (2) RRMS according to the McDonald´s 2017 criteria, (3) MS relapse and insufficient effect of corticosteroids/corticosteroids intolerance, (4) baseline EDSS < 8. Exclusion criteria: (1) progressive form of disease, (2) history of previous TPE. Following parameters were monitored: EDSS changes (before and after corticosteroid treatment, before and after TPE; EDSS after TPE was assessed at the next clinical follow-up at the MS Center), and improvement of EDSS according to the number of procedures and baseline severity of relapse. 115 females (74%) and 40 males (26%) were included. The median age was 41 years (IQR 33-47)-131 patients underwent the pulse corticosteroids treatment and TPE, while 24 patients underwent only TPE without any previous corticosteroid treatment. Median baseline EDSS was 4.5 (IQR 3.5-5.5), median EDSS after finishing steroids was 4.5 (IQR 4.0-5.5). EDSS prior to the TPE was 4.5 (IQR 4-6), EDSS after TPE was 4.5 (IQR 3.5-5.5). We observed a significant improvement in the EDSS after TPE (p < 0.001). Sex differences were seen in TPE effectiveness, with median improvement of EDSS in females being -0.5 (IQR 1-0) and in males being 0 (IQR -0.5 to 0), p = 0.048. There was no difference in EDSS improvement by age category: 18-30 years, 31-40 years, 41-50 years, > 50 (p = 0.94), nor by total TPE count (p = 0.91). In this retrospective study of patients with an aggressive relapse and insufficient effect of intravenous corticosteroid treatment, a significant effect of TPE on EDSS improvement was observed. There was no significant difference in TPE effectivity according to the number of procedures, age, nor severity of a relapse. In this cohort, TPE was more effective in females.

Citing Articles

Beneficial therapeutic plasma exchange response in the treatment of severe relapses in patients with multiple sclerosis.

Mesaros S, Pekmezovic T, Martinovic V, Ivanovic J, Tamas O, Dinic M Acta Neurol Belg. 2024; 124(6):1885-1890.

PMID: 39044118 DOI: 10.1007/s13760-024-02606-w.


Early clinical response and complications of therapeutic plasma exchange in central nervous system demyelinating diseases.

Rashidi M, Naghavi S, Ramezani N, Ashtari F, Shaygannejad V, Hosseini S J Cent Nerv Syst Dis. 2024; 16:11795735241262738.

PMID: 38903856 PMC: 11188695. DOI: 10.1177/11795735241262738.


Therapeutic Plasma Exchange and Multiple Sclerosis Dysregulations: Focus on the Removal of Pathogenic Circulatory Factors and Altering Nerve Growth Factor and Sphingosine-1-Phosphate Plasma Levels.

Tonev D, Momchilova A Curr Issues Mol Biol. 2023; 45(10):7749-7774.

PMID: 37886933 PMC: 10605592. DOI: 10.3390/cimb45100489.

References
1.
Habek M, Barun B, Puretic Z, Brinar V . Treatment of steroid unresponsive relapse with plasma exchange in aggressive multiple sclerosis. Ther Apher Dial. 2010; 14(3):298-302. DOI: 10.1111/j.1744-9987.2009.00794.x. View

2.
Claflin S, Broadley S, Taylor B . The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses. Front Neurol. 2019; 9:1150. PMC: 6335290. DOI: 10.3389/fneur.2018.01150. View

3.
Stork L, Ellenberger D, Beissbarth T, Friede T, Lucchinetti C, Bruck W . Differences in the Reponses to Apheresis Therapy of Patients With 3 Histopathologically Classified Immunopathological Patterns of Multiple Sclerosis. JAMA Neurol. 2018; 75(4):428-435. PMC: 5885209. DOI: 10.1001/jamaneurol.2017.4842. View

4.
Blechinger S, Ehler J, Bsteh G, Winkelmann A, Leutmezer F, Meister S . Therapeutic plasma exchange in steroid-refractory multiple sclerosis relapses. A retrospective two-center study. Ther Adv Neurol Disord. 2021; 14:1756286420975642. PMC: 7844455. DOI: 10.1177/1756286420975642. View

5.
Lipphardt M, Muhlhausen J, Kitze B, Heigl F, Mauch E, Helms H . Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica. J Clin Apher. 2019; 34(4):381-391. DOI: 10.1002/jca.21686. View